What are the detailed diagnostic criteria and management strategies for asthma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Asthma: Comprehensive Diagnosis and Management

DIAGNOSIS

Asthma diagnosis requires demonstrating episodic symptoms of airflow obstruction PLUS objective evidence of reversible airway obstruction on spirometry, defined as FEV1 increase >200 mL AND ≥12% from baseline after inhaling a short-acting β2-agonist. 1

Key Clinical Symptoms to Identify

Look for these specific symptom patterns:

  • Cough (particularly worse at night)
  • Recurrent wheeze
  • Recurrent difficulty breathing
  • Recurrent chest tightness

Critical diagnostic feature: Symptoms must be variable and episodic, not constant 1

Symptom Triggers That Strengthen Diagnosis

Symptoms occur or worsen with:

  • Exercise
  • Viral infections
  • Inhalant allergens (animals with fur/hair, house dust mites, mold, pollen)
  • Irritants (tobacco/wood smoke, airborne chemicals)
  • Weather changes
  • Strong emotional expression (laughing/crying hard)
  • Stress
  • Menstrual cycles
  • Nighttime awakening 1

Essential Diagnostic Testing

Spirometry is mandatory for all patients ≥5 years of age to demonstrate obstruction and assess reversibility 1. Patients' perceptions of airflow obstruction are highly variable, making objective testing essential.

Bronchodilator reversibility test:

  • Administer short-acting β2-agonist
  • Positive if FEV1 increases >200 mL AND ≥12% from baseline
  • Some evidence suggests ≥10% of predicted FEV1 may better separate asthma from COPD 1

When spirometry shows FEV1 ≥70% predicted but suspicion remains:

  • Consider bronchial provocation testing 2
  • If unavailable, may initiate diagnostic anti-inflammatory therapy if:
    • PEF bronchodilation test shows ≥20% increase from baseline, OR
    • FEV1 variability ≥12% and ≥200 mL between two tests, OR
    • Small airway dysfunction (2 of 3 parameters ≤65% predicted: MEF25, MEF50, MMEF) with FeNO ≥35 ppb 2

Physical Examination Findings

Upper respiratory tract:

  • Increased nasal secretion
  • Mucosal swelling
  • Nasal polyps

Chest:

  • Wheezing during normal breathing or prolonged forced exhalation
  • Hyperexpansion of thorax
  • Use of accessory muscles
  • Hunched shoulders
  • Chest deformity

Skin:

  • Atopic dermatitis
  • Eczema

Important caveat: Normal physical examination does NOT rule out asthma due to disease variability between episodes 1

Additional Diagnostic Considerations

Identify allergen sensitivities: Skin-prick tests should be systematically considered, as allergy is frequent in adult asthma and avoiding relevant allergens significantly improves control 3

Key environmental risk factors:

  • House dust mite and Alternaria sensitization/exposure (most important)
  • Viral respiratory infections (RSV, rhinovirus)
  • Tobacco smoke exposure 1

SEVERITY CLASSIFICATION

Assess severity BEFORE initiating therapy to guide initial treatment selection 1

Initial Severity Classification (Treatment-Naive Patients)

Assess two domains: Impairment and Risk

Intermittent Asthma (Step 1):

  • Symptoms <2 times/month
  • No nocturnal symptoms
  • No risk of exacerbations
  • FEV1 >80% predicted 2

Mild Persistent (Step 2):

  • Symptoms >2 days/week but not daily

Moderate Persistent (Step 3-4):

  • Daily symptoms
  • Some limitation of activity

Severe Persistent (Step 5-6):

  • Continuous symptoms
  • Frequent exacerbations
  • Extremely limited activity 1

After treatment initiation: Severity is reclassified based on the lowest treatment step required to maintain control 1


GOALS OF THERAPY

Primary goals target two domains: reducing impairment AND reducing risk 1

Reduce Impairment:

  • Prevent chronic/troublesome symptoms
  • Require infrequent SABA use (≤2 days/week, excluding exercise prevention)
  • Maintain near-normal pulmonary function
  • Maintain normal activity levels (exercise, work, school attendance)

Reduce Risk:

  • Prevent recurrent exacerbations
  • Minimize emergency department visits/hospitalizations
  • Prevent loss of lung function (prevent reduced lung growth in children)
  • Provide optimal pharmacotherapy with minimal adverse effects 1

MANAGEMENT: STEPWISE APPROACH

Inflammation is the primary target of treatment 1. Current evidence strongly supports that all adults, adolescents, children, and most preschoolers with asthma should receive ICS-containing treatment 4. SABA-only treatment is NOT recommended 4.

Step 1: Intermittent Asthma

Preferred: As-needed low-dose ICS-formoterol (anti-inflammatory reliever, AIR-only approach) 4, 2

  • Significantly reduces moderate-to-severe exacerbations compared with SABA monotherapy 2
  • For budesonide-formoterol: 1-2 inhalations as needed, maximum 8 inhalations/day 2

Step 2: Mild Persistent Asthma

Preferred: As-needed low-dose ICS-formoterol 4, 2

Alternative (not preferred):

  • Daily low-dose ICS
  • Leukotriene receptor antagonists (LTRAs)
  • Cromolyn sodium or nedocromil 1

Step 3: Moderate Persistent Asthma

Preferred for patients ≥5 years:

  • Low-dose ICS-LABA combination, OR
  • Increase ICS to medium dose 1

ICS-LABA demonstrates synergistic anti-inflammatory and bronchodilator effects, achieving efficacy equivalent to or better than doubling ICS dose 2

Alternative adjunctive therapy:

  • LTRAs (not preferred compared to LABA in patients ≥12 years) 1
  • Sustained-release theophylline (requires serum monitoring) 1

Step 4: Moderate-Severe Persistent Asthma

Preferred:

  • Medium-to-high dose ICS-LABA 1

Consider adding:

  • Long-acting muscarinic antagonist (LAMA) - triple therapy
  • Triple combination inhalers improve symptoms, lung function, and reduce exacerbations when asthma uncontrolled on medium/high-dose ICS-LABA 2

Step 5-6: Severe Persistent Asthma

Definition of severe asthma: Uncontrolled despite ≥3 months of continuous medium/high-dose ICS-LABA, after treating comorbidities and avoiding environmental triggers, OR worsening when stepping down 2

Management approach:

  1. High-dose ICS-LABA combination

  2. Add biologic therapy for Type 2 asthma:

    • Omalizumab (anti-IgE): For patients ≥12 years with allergies requiring step 5-6 care; must have sensitivity to relevant allergens (dust mite, cockroach, cat, dog) 1
    • Anti-IL-5 agents (mepolizumab, reslizumab): For eosinophilic phenotype 5
    • Anti-IL-5Rα agents: For eosinophilic phenotype 2
    • Anti-IL-4Rα agents: For Type 2 inflammation 2

    Type 2 inflammation criteria: Elevated blood/sputum eosinophils (≥150/μl), and/or elevated FeNO, and/or atopy/elevated total IgE 2

  3. Low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) as LAST resort 2

  4. Consider additional therapies:

    • Azithromycin (250-500 mg three times weekly for 26-48 weeks) for persistent symptoms despite step 5 treatment - reduces exacerbations 2
    • Bronchial thermoplasty for uncontrolled asthma despite optimized treatment when biologics unavailable/inappropriate 2

Critical safety note: Clinicians administering omalizumab must be prepared and equipped to identify and treat anaphylaxis 1


MEDICATION DETAILS

Long-Term Controller Medications

Inhaled Corticosteroids (ICS):

  • Preferred long-term control therapy for all ages 1
  • Long-term treatment at recommended clinical doses is safe
  • Caution: Prolonged high-dose ICS may cause osteoporosis, hypothalamic-pituitary-adrenal axis suppression, increased pneumonia risk 2

Long-Acting β2-Agonists (LABA):

  • Salmeterol and formoterol
  • NEVER use as monotherapy - must be combined with ICS 1
  • Duration of bronchodilation ≥12 hours
  • Preferred adjunctive therapy with ICS in patients ≥12 years 1
  • May prevent exercise-induced bronchospasm, but duration doesn't exceed 5 hours with chronic use; frequent use before exercise discouraged as it may mask poor control 1

Leukotriene Modifiers:

  • LTRAs (montelukast, zafirlukast): Alternative therapy for step 2 care
  • Zileuton (5-lipoxygenase inhibitor): Requires liver function monitoring 1

Anticholinergics:

  • Tiotropium (LAMA): Effective controller in moderate-severe asthma 5

Quick-Relief Medications

Short-Acting β2-Agonists (SABA):

  • Albuterol, levalbuterol, pirbuterol
  • Treatment of choice for acute symptoms and exercise-induced bronchospasm prevention
  • Warning sign: Use >2 days/week for symptom relief (not exercise prevention) indicates inadequate control and need for intensified anti-inflammatory therapy
  • Regularly scheduled daily chronic use NOT recommended 1

Anticholinergics:

  • Ipratropium bromide: Provides additive benefit to SABA in moderate/severe exacerbations in emergency care setting only, NOT hospital setting 1

Systemic Corticosteroids:

  • Oral corticosteroids for moderate/severe exacerbations to speed recovery
  • Short courses often used to gain prompt control
  • Doubling ICS dose for home management is NOT effective 1

MONITORING AND ASSESSMENT

After initiating therapy, emphasis shifts from severity to CONTROL assessment 1

Follow-Up Schedule

  • Every 2-6 weeks while gaining control or stepping up therapy 1
  • Every 1-6 months once control achieved (interval depends on treatment step) 1
  • Every 3 months if stepping down therapy anticipated 1

At Every Visit Assess:

  1. Asthma control (symptoms, SABA use, activity limitation)
  2. Medication technique (inhaler technique)
  3. Written asthma action plan review
  4. Patient adherence
  5. Patient concerns 1

Spirometry Monitoring

Obtain spirometry:

  • At initial assessment
  • After treatment initiated and symptoms/PEF stabilized
  • During progressive/prolonged loss of control
  • At least every 1-2 years (more frequently if not well controlled) 1

Low FEV1 indicates current obstruction AND risk for future exacerbations 1

Biomarker Monitoring

Fractional Exhaled Nitric Oxide (FeNO):

  • Reflects Type 2 airway inflammation
  • ≥35 ppb suggests eosinophilic inflammation 2

Peripheral Blood Eosinophils:

  • ≥150/μl identifies eosinophilic phenotype/Type 2 inflammation
  • Key biomarker to predict and evaluate biologic response 2

Induced Sputum Eosinophils:

  • Gold standard for airway inflammation assessment
  • Used for phenotype classification, corticosteroid response prediction, exacerbation risk assessment 2

Peak Flow Monitoring

Consider daily peak flow monitoring for:

  • Moderate/severe persistent asthma
  • History of severe exacerbations
  • Patients who poorly perceive airway obstruction 1

COMORBIDITY MANAGEMENT

Identify and treat comorbid conditions that affect asthma control 1:

  • Sinusitis
  • Rhinitis (allergic and non-allergic)
  • Gastroesophageal reflux disease (GERD)
  • Obstructive sleep apnea (OSA)
  • Obesity
  • Stress/depression
  • Anxiety

Psychosocial assessment (anxiety/depression scales) should be performed if patients have dyspnea/chest tightness after routine therapy with normalized lung function, eosinophils, and FeNO 2


ENVIRONMENTAL CONTROL

Multifaceted approaches necessary; single interventions generally ineffective 1

Key Strategies:

  • Reduce exposure to house dust mites and Alternaria (most important allergens) 1
  • Avoid tobacco smoke exposure
  • Minimize exposure to identified allergens based on sensitivity testing
  • Reduce irritant exposures (wood smoke, airborne chemicals)

Immunotherapy Considerations:

Subcutaneous immunotherapy:

  • Consider for patients with allergies requiring step 2-4 care (mild/moderate persistent asthma)
  • When clear relationship between symptoms and allergen exposure exists
  • Clinicians must be prepared to treat anaphylaxis 1

Sublingual immunotherapy (house dust mite):

  • For HDM-sensitized adolescents/adults with FEV1 >70% predicted
  • May reduce symptoms and ICS dose if symptoms persist despite low-to-medium dose ICS-containing therapy 2

EXACERBATION MANAGEMENT

Severity Classification

Severe exacerbation: FEV1 or PEF <40% predicted - indicates potential benefit of adjunctive therapies 1

Discharge goal: FEV1 or PEF ≥70% predicted 1

Emergency Treatment

Medications:

  1. Albuterol (or levalbuterol) - primary bronchodilator 1
  2. Oxygen 1
  3. Oral systemic corticosteroids (emphasize oral route) 1
  4. Anticholinergics (ipratropium) - use in emergency care, NOT hospital care 1

For severe exacerbations unresponsive to initial treatment:

  • Magnesium sulfate 1
  • Heliox 1

At Discharge:

  • Initiate or continue ICS 1
  • Provide written asthma action plan
  • Schedule follow-up within 2-6 weeks
  • Review inhaler technique
  • Assess and address factors contributing to exacerbation

PATIENT EDUCATION

Education should occur at ALL points of care: clinic settings, emergency departments, hospitals, pharmacies, schools, community settings, and patients' homes 1

Essential Education Components:

  1. Written Asthma Action Plan (develop in partnership with patient):

    • Daily management instructions (long-term control medications, environmental control)
    • How to recognize worsening asthma
    • How to adjust medications
    • When to seek medical care 1
  2. Self-Monitoring:

    • Teach recognition of inadequate control
    • Either symptom or peak flow monitoring (benefits similar for most patients) 1
    • Peak flow monitoring particularly helpful for patients with difficulty perceiving symptoms, history of severe exacerbations, or moderate/severe asthma 1
  3. Medication Technique:

    • Correct inhaler technique (use of devices)
    • Difference between long-term control and quick-relief medications 1
  4. Environmental Control:

    • Avoiding triggers and allergens
  5. Cultural Considerations:

    • Tailor education to literacy level
    • Appreciate cultural beliefs and practices in asthma management 1

Involve entire healthcare team: physicians, nurses, pharmacists, respiratory therapists, asthma educators 1


RED FLAGS: RISK FACTORS FOR ASTHMA-RELATED DEATH

Immediate specialist referral warranted if ANY of the following present 2:

  1. History requiring intubation and mechanical ventilation
  2. Hospitalization or emergency visit for asthma in past year
  3. Currently using or recently stopped oral corticosteroids
  4. No current ICS use
  5. Overuse of SABA (>1 canister salbutamol/month or equivalent)
  6. Psychiatric illness or psychosocial problems (including sedative use)
  7. Poor adherence
  8. Confirmed food allergy history
  9. Comorbidities: pneumonia, diabetes, arrhythmias

Any patient with ≥2 exacerbations in one year should be referred to pulmonology 6


SPECIAL POPULATIONS AND PHENOTYPES

Cough Variant Asthma (CVA)

  • Treatment principles same as typical asthma
  • ICS-LABA recommended as first choice, use >8 weeks 2
  • For poor response with severe inflammation: consider adding LTRA or short-term oral corticosteroids (10-20 mg/day for 3-5 days) 2

Aspirin-Induced Asthma (AIA)

  • Most effective prevention: avoid aspirin 2
  • Desensitization therapy may be considered for patients requiring high-dose ICS, failed conventional treatment for nasal inflammation/polyposis, or requiring aspirin for other diseases 2

Asthma with Chronic Rhinosinusitis with Nasal Polyps

  • May benefit from anti-IgE, anti-IL-5, anti-IL-5Rα, or anti-IL-4Rα monoclonal antibodies 2

Asthma-COPD Overlap (ACO)

Consider diagnosis if asthma patient has:

  • Persistent airflow limitation (FEV1/FVC <70% post-bronchodilator)
  • History of noxious gas/substance exposure (smoking ≥10 pack-years)
  • Emphysema on high-resolution CT
  • Decreased diffusion capacity after 3-6 months standardized treatment 2

Fungal-Sensitized Asthma

  • Antifungal drugs can reduce airway inflammation and systemic corticosteroid dose 2
  • Biologic therapies (anti-IgE, anti-IL-5, anti-IL-5Rα, anti-IL-4Rα) can reduce exacerbations and improve control 2

CLINICAL REMISSION

Patients achieving ≥1 year of symptom-free status, no exacerbations, normal/near-normal lung function, and no need for oral corticosteroids after biologic or other anti-asthma therapy may be considered to have achieved "clinical remission" 2

References

Research

[Guidelines for the prevention and management of bronchial asthma (2024 edition)].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2025

Research

[Diagnosing asthma in adults].

La Revue du praticien, 2025

Research

2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes.

American journal of respiratory and critical care medicine, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.